Search Results - "Baweja, R"

Stability of Disruptive Mood Dysregulation Disorder Symptoms (Irritable-Angry Mood and Temper Outbursts) Throughout Childhood and Adolescence in a General Population Sample by Mayes, S. D., Mathiowetz, C., Kokotovich, C., Waxmonsky, J., Baweja, R., Calhoun, S. L., Bixler, E. O.

“…DSM-5 Disruptive Mood Dysregulation Disorder (DMDD) is a controversial new diagnosis. The DSM-5 conceptualizes DMDD as persistent and chronic, but the…”
Get full text

A polyherbal vaginal pessary with spermicidal and antimicrobial action: evaluation of its safety by Bagga, R., Raghuvanshi, P., Gopalan, S., Das, S.K., Baweja, R., Suri, S., Malhotra, D., Khare, S., Talwar, G.P.

“…A polyherbal vaginal pessary (Praneem) has been formulated that has antimicrobial properties against genital pathogens in addition to spermicidal action. Thus,…”
Get full text

Sleep problems in children by Baweja, R, Calhoun, S, Baweja, R, Singareddy, R

“…Sleep complaints and sleep disorders are common during childhood and adolescence. The impact of not getting enough sleep may affect children's' physical health…”
Get more information

Does percent reduction in seizure frequency correlate with plasma concentration of anticonvulsant drugs? Experience with four anticonvulsant drugs by Mahmood, Iftekhar, Tammara, Vijay K., Baweja, Raman K.

“…Objective To investigate the relationship between the percentage reduction in seizure frequency in patients with epilepsy and plasma concentrations after oral…”
Get full text

Utility of Cholinesterase Inhibition in The PK PD, and BA Studies of Anti-Cholinesterases (Anti-AChE) by Al‐Habet, S., Baweja, R., Mishina, E.

“…Clinical Pharmacology & Therapeutics (1999) 65, 169–169; doi:…”
Get full text

Disruptive mood dysregulation disorder (DMDD) symptoms in children with autism, ADHD, and neurotypical development and impact of co-occurring ODD, depression, and anxiety by Mayes, S.D., Waxmonsky, J., Calhoun, S.L., Kokotovich, C., Mathiowetz, C., Baweja, R.

“…•Disruptive mood dysregulation disorder (DMDD) is a controversial new DSM-5 diagnosis.•Mothers rated irritable-angry mood and temper outbursts in 1593…”
Get full text

Disruptive mood dysregulation disorder: current insights by Baweja, Raman, Mayes, Susan D, Hameed, Usman, Waxmonsky, James G

“…Disruptive mood dysregulation disorder (DMDD) was introduced as a new diagnostic entity under the category of depressive disorders in Diagnostic and…”
Get full text

Data Mining Application in Segmenting Customers with Clustering by Chugh, Saryu, Baweja, Vanshita R

“…This paper describes regarding competition level that is raised between the organizations to retain the customers. To have a command in e-business and other…”
Get full text

Transcriptional Control of the Mycobacterial embCAB Operon by PknH through a Regulatory Protein, EmbR, In Vivo by SHARMA, Kirti, GUPTA, Meetu, PATHAK, Monika, GUPTA, Nidhi, KOUL, Anil, SARANGI, Smilona, BAWEJA, Renu, SINGH, Yogendra

“…Article Usage Stats Services JB Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Psychiatric morbidity in patients with transverse myelitis and stroke: A comparison by Baweja, Raman, Avasthi, Ajit, Chakrabarti, Subho, Prabhakar, Sudesh

“…Psychiatric morbidity may be highly prevalent in transverse myelitis (TM), but data on this aspect are limited. To assess psychiatric morbidity in a clinical…”
Get full text

Competitive binding between cocaine and various drugs to synthetic levodopa melanin by Baweja, R, Sokoloski, T D, Patil, P N

Get more information

Binding characteristics of drugs to synthetic levodopa melanin by Shimada, K, Baweja, R, Sokoloski, T, Patil, P N

“…To define binding characteristics of drugs, levodopa melanin was prepared with the aid of mushroom tyrosinase. The binding of radiolabeled substances was…”
Get more information

PI-2Drug interaction studies -- study design, data analysis, and implications for dosing and labeling: Current opinion by HUANG, S, REYNOLDS, K, STRONG, J, NALLANI, S, LESKO, L, TEMPLE, R, ABRAHAM, S, ALHABET, S, BAWEJA, R, CHUNG, S

Get full text

New Era in Drug Interaction Evaluation: US Food and Drug Administration Update on CYP Enzymes, Transporters, and the Guidance Process by Huang, Shiew-Mei, Strong, John M., Zhang, Lei, Reynolds, Kellie S., Nallani, Srikanth, Temple, Robert, Abraham, Sophia, Habet, Sayed Al, Baweja, Raman K., Burckart, Gilbert J., Chung, Sang, Colangelo, Philip, Frucht, David, Green, Martin D., Hepp, Paul, Karnaukhova, Elena, Ko, Hon-Sum, Lee, Jang-Ik, Marroum, Patrick J., Norden, Janet M., Qiu, Wei, Rahman, Atiqur, Sobel, Solomon, Stifano, Toni, Thummel, Kenneth, Wei, Xiao-Xiong, Yasuda, Sally, Zheng, Jenny H., Zhao, Hong, Lesko, Lawrence J.

“…Predicting clinically significant drug interactions during drug development is a challenge for the pharmaceutical industry and regulatory agencies. Since the…”
Get full text

PI-2 by Huang, S. M., Reynolds, K. S., Strong, J. M., Nallani, S. C., Lesko, L. J., Temple, R., Abraham, S., Alhabet, S., Baweja, R., Chung, S. M., Colangelo, P., Collins, J. M., Frucht, D., Green, M. D., Hepp, P., Kavanagh, R., Ko, H. S., Marroum, P., Qiu, W., Rahman, A., Sobel, S., Stifano, T., Wei, X., Yasuda, S. U., Zhang, L.

“…AIMS Creation of a concept paper that reflects the Agency's current view that the metabolism of a new drug should be adequately characterized and its potential…”
Get full text

Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications by Bhattaram, Venkatesh A, Booth, Brian P, Ramchandani, Roshni P, Beasley, B Nhi, Wang, Yaning, Tandon, Veneeta, Duan, John Z, Baweja, Raman K, Marroum, Patrick J, Uppoor, Ramana S, Rahman, Nam Atiqur, Sahajwalla, Chandrahas G, Powell, J Robert, Mehta, Mehul U, Gobburu, Jogarao V S

“…The value of quantitative thinking in drug development and regulatory review is increasingly being appreciated. Modeling and simulation of data pertaining to…”
Get full text

Nonlinear mixed effects modeling of single dose and multiple dose data for an immediate release (IR) and a controlled release (CR) dosage form of alprazolam by HOSSAIN, M, WRIGHT, E, BAWEJA, R, LUDDEN, T, MILLER, R

“…NONMEM was applied to single dose and multiple dose bioavailability data for an immediate release (IR) and a controlled release (CR) dosage form of alprazolam…”
Get full text

Draft guidance for industry extended-release solid oral dosage forms. Development, evaluation and application of in vitro-in vivo correlations by Malinowski, H, Marroum, P, Uppoor, V R, Gillespie, W, Ahn, H Y, Lockwood, P, Henderson, J, Baweja, R, Hossain, M, Fleischer, N, Tillman, L, Hussain, A, Shah, V, Dorantes, A, Zhu, R, Sun, H, Kumi, K, Machado, S, Tammara, V, Ong-Chen, T E, Mahayni, H, Lesko, L, Williams, R

Get more information

Indian Council of Medical Research. Task Force on Hormonal Contraception: Phase II randomized clinical trial with norethisterone oenanthate 50 mg alone and in combination with 5 mg or 2.5 mg of either estradiol valerate or cypionate as a monthly injectable contraceptive by Baweja, R, Bhattacharya, S K, Choudhury, S D, Krishna, U, Manuel, M, Phillips, F S, Datey, S, Kumar, S, Mehta, S, Saxena, N C

“…A Phase II multicentric study was carried out to compare the different contraceptive treatment schedules of the monthly injectable consisting of norethisterone…”
Get more information

Comparative evaluation of contraceptive efficacy of norethisterone oenanthate (200 mg) injectable contraceptive given every two or three monthly. Indian Council of Medical Research Task Force on Hormonal Contraception by Banerjee, S K, Baweja, R, Bhatt, R V, Chatterjee, A, Choudhury, S D, Coyaji, B, Engineer, A D, Gogoi, M P, Hingorani, V, Kasturilal

“…A total of 2388 subjects, 1181 for 60 +/- 5-day and 1207 for 90 +/- 5-day treatment regimen with norethisterone oenanthate (NET OEN) 200 mg injection, were…”
Get more information